These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7046923)

  • 1. Tardive dyskinesia: pharmacology and clinical implications.
    Goetz CG; Weiner WJ; Nausieda PA; Klawans HL
    Clin Neuropharmacol; 1982; 5(1):3-22. PubMed ID: 7046923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia.
    Goetz CG; Klawans HL
    Neurol Clin; 1984 Aug; 2(3):605-14. PubMed ID: 6152483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia: review and update.
    Klawans HL; Goetz CG; Perlik S
    Am J Psychiatry; 1980 Aug; 137(8):900-8. PubMed ID: 6106395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia and essential fatty acids.
    Vaddadi K; Hakansson K; Clifford J; Waddington J
    Int Rev Psychiatry; 2006 Apr; 18(2):133-43. PubMed ID: 16777667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tardive dyskinesia: a review].
    Crespo Facorro B; Payá González B; Ruiz Fernández V; Carbonell Masia C
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(2):118-27. PubMed ID: 9245189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine in tardive dyskinesia: observations from human and animal model studies.
    Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tardive dyskinesia: I. Physiopathology and treatment].
    Andrade LA; Bertolucci PH; Pereira JS
    Arq Neuropsiquiatr; 1984 Dec; 42(4):362-70. PubMed ID: 6152578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of tardive dyskinesia: current update.
    Simpson GM; Pi EH; Sramek JJ
    Drugs; 1982 May; 23(5):381-93. PubMed ID: 7047137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
    Zivković SA; Costa G; Bond G; Abu-Elmagd KM
    Acta Neurol Scand; 2008 May; 117(5):351-3. PubMed ID: 17995990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia.
    Soares-Weiser K; Fernandez HH
    Semin Neurol; 2007 Apr; 27(2):159-69. PubMed ID: 17390261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Hadj Tahar A; Bézard E; Grondin R; Gross CE; Bédard PJ
    Rev Neurol (Paris); 2003 Dec; 159(12):1125-42. PubMed ID: 14978413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.